MarginsXMarginsX
Home › Markets › Health Care › SNY

Sanofi ADS (SNY)

SNY trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$48.39
+0.04% on the day
Market cap
$118.0B
Large cap
Revenue
Foreign filer: no machine-readable annual figure in SEC data
Net income
Foreign filer: no machine-readable annual figure in SEC data

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerSNY on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryFrance
IPO yearNot reported by the screener
SEC CIK0001121404
SEC industry codePharmaceutical Preparations
Incorporated inFrance

Financials

Foreign filer: no machine-readable annual figure in SEC data.

Warning signs

Cash runway
Cash-flow positive
7.7B EUR cash at December 31, 2025
Share count, 1 year
-3.5%
2024-12-31 to 2025-12-31 · -3.3% over 3 years
Going-concern doubt
No
20-F filed February 17, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.20-F 2026-02-17
Cash and burn7.7B EUR cash; operating cash flow 2.7B EUR a quarter.Report 2025-12-31
Shares outstanding2,438,854,192 (2025-12-31); 2,526,245,442 a year earlier; 2,521,671,464 three years earlier. the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures.Cover page 2025-12-31
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorForvis Mazars SA, Levallois-Perret, FrancePCAOB Form AP 2026-03-18
Late filings, 12 months2 NT noticesNT 11-K 2026-06-30
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Annual results

Fiscal yearRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
FY 2025
2025-12-31
Not filed7.8B EUR10.8B EUR7.7B EUR18.7B EURNeeds four quarters20-F 2026-02-17
FY 2024
2024-12-31
Not filed5.6B EUR9.1B EUR7.4B EUR16.1B EURNeeds four quarters20-F 2026-02-17
FY 2023
2023-12-31
Not filed5.4B EUR10.3B EUR8.7B EUR16.5B EURNeeds four quarters20-F 2026-02-17
FY 2022
2022-12-31
Not filed8.4B EUR10.5B EUR12.7B EUR19.2B EURNeeds four quarters20-F 2025-02-13
FY 2021
2021-12-31
Not filed6.2B EUR10.5B EUR10.1B EUR20.3B EURNeeds four quarters20-F 2024-02-23
FY 2020
2020-12-31
Not filed12.3B EUR7.4B EUR13.9B EUR22.6B EURNeeds four quarters20-F 2023-02-24
FY 2019
2019-12-31
Not filed2.8B EUR7.7B EUR9.4B EUR24.6B EURNeeds four quarters20-F 2022-02-23
FY 2018
2018-12-31
Not filed4.3B EUR5.5B EUR6.9B EUR24.6B EURNeeds four quarters20-F 2021-03-04

From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months). Amounts in EUR.

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52025-10-29
Latest annual report20-F2026-02-17
Latest quarterly / interim6-K2026-10-30

Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+2.8%
1 month+23.6%
3 months+10.5%
Year to date-0.2%
1 year-7.6%
From 52-week high-7.2%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
BMYBristol-Myers Squibb Company$62.93-0.79%$128.6B
VRTXVertex Pharmaceuticals Incorporated$537.79-0.15%$136.4B
GSKGSK plc$50.41-0.08%$102.0B
REGNRegeneron Pharmaceuticals Inc.$952.40-0.32%$98.5B
PFEPfizer Inc.$28.86-0.10%$164.5B
NVONovo Nordisk A/S$41.60-0.07%$184.2B
ABTAbbott Laboratories$107.45-0.99%$186.1B
TAKTakeda Pharmaceutical Company Limited$21.59+0.75%$68.2B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier